213TiP - PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist Megestrol Acetate versus letrozole aloNE in post-menopausal patients with ER-posit...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Early Stage
Breast Cancer
Presenter Sanjeev Kumar
Citation Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362
Authors S.S. Kumar1, G. Dougall2, A. Vallier2, L. Jones3, W. Qian2, E. Provenzano4, C. Caldas4, P. Pantziarka5, J. Carroll1, R. Baird4
  • 1Cambridge Institute, Cancer Research Uk, University of Cambridge, CB2 0RE - Cambridge/GB
  • 2Cambridge Cancer Trials Centre, Addenbrooke's Hospital, CB2 0QQ - Cambridge/GB
  • 3Cambridge Breast Cancer Research Unit, University of Cambridge, CB2 0QQ - Cambridge/GB
  • 4Cambridge Biomedical Campus, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, CB2 0QQ - Cambridge/GB
  • 5Repurposing Drugs In Oncology, Anticancer Fund, Kingston upon Thames/GB

Abstract

Background

Recent preclinical findings have been published which provide new insights into the functional cross-talk between the estrogen receptor (ER) and the progesterone receptor (PR) in breast cancer (Mohammed et al., Nature, 2015). Addition of a PR agonist to anti-estrogens directly modifies ERa chromatin binding and the transcriptional response in breast cancer cells, and is anti-proliferative in vitro and in vivo. Megestrol Acetate (MA), an off-patent semi-synthetic derivative of progesterone, has been licensed for many years as a treatment for ER+ metastatic breast cancer. There is also good evidence for the effectiveness of MA as a supportive therapy to ameliorate endocrine therapy-related hot flushes.

Trial design

PIONEER is a three-arm, open label, multi-centre randomised phase II pre-surgical window trial evaluating effects of 15 days of preoperative therapy with Letrozole (LET), or LET plus MA 40mg, or LET plus MA 160mg in postmenopausal women with newly diagnosed, ER+ HER2- invasive primary breast cancer. Patients are being recruited in Cambridge, with 5-6 other UK sites due to open in q3/4 2017.Table:

213TiP 3-arm randomisation

Arm ALET 2.5mg daily
Arm BLET 2.5mg daily + MA 40mg daily
Arm CLET 2.5mg daily + MA 160mg daily

The primary endpoint is % change in proliferation between baseline and day 15 tumour biopsies, measured by Ki67 immunohistochemical (IHC) assessment. Secondary endpoints include: expression of Aurora Kinase A, Caspase 3 and Androgen receptor/PR/EMT markers by IHC; and safety endpoints. Exploratory endpoints include: transcription factor mapping (ChIP-seq) on paired fresh-frozen tumour samples. Patients are randomised in a 1: 1.5: 1.5 ratio for arms A: B: C. Based on results from previous clinical trials, a mean 66% reduction in Ki67 is anticipated for LET alone (arm A), and a 77.5% reduction for combination arms B and C, based on preclinical data. A recruitment total of 189 patients is required. Pioneer will help determine if there is value in conducting a follow-on adjuvant study to investigate the longer term benefit of combining an aromatase inhibitor with MA, and if so, at what dose (40mg vs. 160mg).

Clinical trial identification

EudraCT Number: 2016-003752-79 MHRA/REC number: v2.0 5th June 2017

Legal entity responsible for the study

Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge

Funding

Anticancer Fund

Disclosure

All authors have declared no conflicts of interest.